FDA will expedite review of cancer drug Istodax for expanded use

02/28/2011 | Reuters

The FDA granted priority-review status to Celgene's Istodax for use in patients with peripheral T-cell lymphoma who have undergone prior treatment. The agency, which approved the drug for cutaneous T-cell lymphoma, is expected to decide by June 17 on the expanded use.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY